How can drug manufacturers leverage real-world data (RWD) without running afoul of statutory regulations or the trust of patients and data-sharing partners? The likelihood people can be identified from RWD varies greatly based on the type of data and its context of use – including analysis of anonymized data acquired from 3rd parties (especially for rare diseases). That’s why we recommend the 5 Safes of Risk-Based Anonymization as your foundational framework for earning trust. It helps you safely turn RWD into business advantage including optimized clinical trial design and drug differentiation.
In this webinar you’ll gain key insights to help your company continue to earn trust for linking and analyzing vast stores of insight-rich data, needed to compete competitively, and drive advances in patient health.
Who Should Attend:
Health and life sciences professionals involved in:
For questions please contact Martha Devia: firstname.lastname@example.org
Information provided by you is stored on our database and may be used for sending you additional information about IQVIA group services. Such information may be transferred for this purpose to IQVIA companies based in other countries. If you do not wish to receive further information about IQVIA group services please email email@example.com. Copyright © 2018 IQVIA INC and its affiliates. All rights reserved.